<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36930103</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>102</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>17</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Meta-analysis of clinical risk factors of patients with systemic lupus erythematosus complicated with invasive fungal infection.</ArticleTitle><Pagination><StartPage>e29652</StartPage><MedlinePgn>e29652</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e29652</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000029652</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To systematically evaluate the clinical risk factors of patients with systemic lupus erythematosus (SLE) complicated with invasive fungal infection (IFI) among patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A meta-analysis was performed of all the literatures germane to estimate the clinical risk factors of patients with SLE complicated with IFI from published clinical trials from 1990 to April 2022. Mean differences, odds ratio and 95% confidence intervals were calculated, and the meta-analysis was conducted with Stata 12.0 software (StataCorp, College Station, TX).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 14 clinical research involving 1129 patients were included. The results of meta-analysis demonstrated that immunosuppressant, glucocorticoids, systemic lupus erythematosus disease activity index score, antibiotic were risk factors associated with IFI in SLE patients. However, age, sex, course of disease, leukopenia, lymphopenia, C- reactive protein and hypoproteinemia were not the risk factors associated with IFI in patients with SLE.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results indicate that immunosuppressant, glucocorticoids, systemic lupus erythematosus disease activity index score, antibiotic were risk factors for IFI in SLE patients. However, high quality of multicenter, large sample size-controlled trials are needed to validate the result.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0629-8648</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, The Third Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chifeng</LastName><ForeName>Liao</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Dermatology and Department of Dermatology, No.1 Hospital, Anhui Medical University, Hefei, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qinghuan</LastName><ForeName>Zhu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Dermatology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zichan</LastName><ForeName>Huang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Dermatology, The Third Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jianmin</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Dermatology, The Third Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danqi</LastName><ForeName>Deng</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Dermatology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072742" MajorTopicYN="Y">Invasive Fungal Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007970" MajorTopicYN="Y">Leukopenia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no funding and conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>17</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36930103</ArticleId><ArticleId IdType="pmc">PMC10019271</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000029652</ArticleId><ArticleId IdType="pii">00005792-202303170-00040</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Durcan L, O&#x2019;Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393:2332&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">31180030</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology. 2012;51:1145&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">22271756</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong SJ, Choi H, Lee HS, et al. . Incidence and risk factors of infection in a single cohort of 110 adults with systemic lupus erythematosus. Scand J Infect Dis. 2009;41:268&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">19172435</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HS, Tsai WP, Leu HS, et al. . Invasive fungal infection in systemic lupus erythematosus: an analysis of 15 cases and a literature review. Rheumatology (Oxford). 2007;46:539&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">17043051</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinicki JP, Catalan Pellet S, Pappalardo C, et al. . Invasive fungal infections in Argentine patients with systemic lupus erythematosus. Lupus. 2013;22:892&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23861029</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiechtner JJ, Montroy T. Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial. Lupus. 2014;23:905&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4232266</ArticleId><ArticleId IdType="pubmed">24795067</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng C-T, Lee N-Y, Liu M-F, et al. . A retrospective study of catastrophic invasive fungal infections in patients with systemic lupus erythematosus from southern Taiwan. Lupus. 2010;19:1204&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20515999</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva PSLD, Reis ME, Aguiar VE, et al. . Unplanned extubation in the neonatal ICU: a systematic review, critical appraisal, and evidence-based recommendations. Respir Care. 2012;58:1237&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">23271815</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CD, Wang XD, Ye S, et al. . Clinical features, prognostic and risk factors of central nervous system infections in patients with systemic lupus erythematosus. Clin Rheumatol. 2007;26:895&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">17021668</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Mart&#xed;nez MU, Herrera-van Oostdam D, Rom&#xe1;n-Acosta S, et al. . Invasive fungal infections in patients with systemic lupus erythematosus. J Rheumatol. 2012;39:1814&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22707608</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H, You Y, Liu P, et al. . Clinical study of invasive fungal infection secondary to systemic lupus erythematosus. J Cent South Univ (Med Sci). 2013;38:182&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">23456067</ArticleId></ArticleIdList></Reference><Reference><Citation>Rong F. Risk factors of pulmonary fungal infection in systemic lupus erythematosus. Med Recapitulate. 2014:172&#x2013;4.</Citation></Reference><Reference><Citation>Santamar&#xed;a-Alza Y, S&#xe1;nchez-Bautista J, Fajardo-Rivero JF, et al. . Invasive fungal infections in Colombian patients with systemic lupus erythematosus. Lupus. 2018:096120331876374.</Citation><ArticleIdList><ArticleId IdType="pubmed">29536803</ArticleId></ArticleIdList></Reference><Reference><Citation>Lao M, Wang X, Ding M, et al. . Invasive fungal disease in patients with systemic lupus erythematosus from Southern China: a retrospective study. Lupus. 2019;28:77&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">30526329</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen GL, Chen Y, Zhu CQ, et al. . Invasive fungal infection in Chinese patients with systemic lupus erythematosus. Clin Rheumatol. 2012;31:1087&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">22476206</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Yuntao Z, Airu G, et al. . The clinical analysis for 72 cases of systemic lupus erythematosus with fungal infection. Mod prev Med. 2013:164&#x2013;5 + 8.</Citation></Reference><Reference><Citation>Silva MF, Ferriani MP, Terreri MT, et al. . A multicenter study of invasive fungal infections in patients with childhood-onset systemic lupus erythematosus. J Rheumatol. 2015;42:2296&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">26568586</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhen T, LiXiaoMei, Li X-P, Guosheng W, et al. . The etiopathogenisis of fungal infections induced by systemic lupus erythematosus. J Pract Med. 2015;000:2134&#x2013;7.</Citation></Reference><Reference><Citation>Yun G, Xin T, Yuzi D, et al. . Analysis of 27 cases of patients with systemic lupus erythematosus accompanied with invasive fungal disease. Chin J Dermatovenereol. 2017;031:980&#x2013;3.</Citation></Reference><Reference><Citation>Xueyan L. Investigation of fungal infection in patients with systemic lupus erythematosus. Chin J Leprosy Dermatol. 2011:32&#x2013;3.</Citation></Reference><Reference><Citation>Xin T, Yun G, Danqi D, et al. . Analysis the cliIlical risk factors of systemic lupus erythematosus patients with invasive fungal disease. J Dermatol Venereal Dis. 2016:79&#x2013;83.</Citation></Reference><Reference><Citation>Al-Rayes H, Al-Swailem R, Arfin M, et al. . Systemic lupus erythematosus and infections: a retrospective study in Saudis. Lupus. 2007;16:755&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">17728372</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LR, Barber CE, Johnson AS, et al. . Invasive fungal disease in systemic lupus erythematosus: a systematic review of disease characteristics, risk factors, and prognosis. Semin Arthritis Rheum. 2014;44:325&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">25129259</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X, Jian LI, Zhang L, et al. . Pathogenic characteristics, drug resistance and risk factors of systemic lupus erythematosus with fungal infection. Lab Med Clin. 2017.</Citation></Reference><Reference><Citation>Lao M, Zhan Z, Su F, et al. . Invasive mycoses in patients with connective tissue disease from Southern China: clinical features and associated factors. Arthritis Res Ther. 2019;21:71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6416859</ArticleId><ArticleId IdType="pubmed">30867045</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandman-Goddard G, Shoenfeld Y. SLE and Infections. Infect Autoimmun. 2004;25:491&#x2013;503.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>